Kynamro Liver Safety Data Faces FDA Advisory Committee Gauntlet
This article was originally published in The Pink Sheet Daily
Questions about liver toxicity have dogged Genzyme/Isis’ Kynamro (mipomersen), despite robust LDL-lowering. An FDA panel review in October will tell whether seemingly reassuring safety data from a long-term extension study will do the trick for U.S. approval.
You may also be interested in...
Sanofi’s Genzyme business unit and Isis submitted an NDA for mipomersen, a first-in-class cholesterol-lowering antisense drug, in an orphan population of high-risk patients with a rare genetic cardiovascular disease – with an assist from three Phase III clinical trials from other, larger, high-risk populations, to help inform regulators.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.